Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.

Created on 12 Sep 2026

Authors

András Miklós Dorgó, Lilla Gunkl-Tóth, György Nagy

Published in

International journal of molecular sciences. Volume 27. Issue 4. Feb 15, 2026. Epub Feb 15, 2026.

Abstract

Difficult-to-treat (D2T) rheumatoid arthritis (RA) remains a major clinical challenge, affecting a significant proportion of patients who experience persistent symptoms despite multiple therapeutic regimens. This narrative review provides a comprehensive overview of potential molecular and cellular mechanisms that may underlie the D2T RA phenotype. We synthesize evidence across a broad biological landscape-the role of genetic and epigenetic factors, autoantibodies, and diverse immune cell subsets is detailed in the context of therapeutic resistance. Furthermore, we examine the potential role of synovial signatures and stromal cell-mediated pathways, which may drive chronicity independently of traditional immune targets. The review highlights the complex interplay of peripheral and central determinants that contribute to patient-reported outcomes such as pain. We also discuss comorbid conditions, environmental factors such as smoking and nutrition, and treatment-related factors relevant to the D2T population. By integrating these aspects, this work aims to facilitate better stratification and the identification of novel therapeutic targets for refractory disease.

PMID:
41751996
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement